Bio-FD&C Co

Bio-FD&C Co Net Debt / EBITDA

The Net Debt to EBITDA of Bio-FD&C Co (251120.KQ) as of Oct 21, 2026 is -8.56. In the previous year, Net Debt to EBITDA was -7.52 — a change of 13.84% (lower).

Net Debt / EBITDA

-8.56

YoY

13.84%

Last updated:

Net Debt to EBITDA of Bio-FD&C Co is 2024 -8.56 . Net Debt to EBITDA of Bio-FD&C Co was 2023 -7.52 . It decreases by 13.84% lower compared to the previous year.

The Bio-FD&C Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
-2.92 KRW
Jan 1, 2019
-1.28 KRW
Jan 1, 2020
-1.01 KRW
Jan 1, 2021
-1.16 KRW
Jan 1, 2022
-7.43 KRW
Jan 1, 2023
-7.52 KRW
Jan 1, 2024
-8.56 KRW
The Bio-FD&C Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-8.56+13.84%
-7.52+1.15%
-7.43+538.74%
-1.16+15.14%
-1.01-20.83%
-1.28-56.30%
-2.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio-FD&C Co Stock analysis

What does Bio-FD&C Co do? Bio-FD&C Co., Ltd. develops bio and health technologies, focusing on manufacturing and selling soybean callus culture extract, clock stem cell, centella asiatica, callus extract, aloe barbadensis phytoplaceta extract, prunus mume phytoplacenta extract, secale cereale adventitious root extract, and acanthopanax koreanum adventitious root culture extract. These products serve as key materials for cosmeceuticals, health functional foods, and pharmaceuticals, targeting companies in the cosmetics, health supplement, and pharmaceutical industries. The company generates revenue through direct sales of these specialized extracts to manufacturers who incorporate them into their final products. The firm's product portfolio includes unique bioactive compounds like centella asiatica and prunus mume phytoplacenta extract, which are used in high-value applications within the cosmeceutical and pharmaceutical sectors. By supplying these specialized ingredients, Bio-FD&C Co., Ltd. caters to clients seeking natural, plant-based solutions for product development. Its focus on extract-based materials positions it as a supplier for companies developing innovative health and beauty products. Bio-FD&C Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-FD&C Co stock

Net Debt to EBITDA of Bio-FD&C Co is -8.56 in 2024.

Net Debt to EBITDA of Bio-FD&C Co changed from -7.52 to -8.56, representing a 13.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Bio-FD&C Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Bio-FD&C Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio-FD&C Co

All Key Metrics — Bio-FD&C Co